Skip to main content

Table 3 Adverse events and surgical complications by sarcopenia at baseline

From: Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy

Variable

No sarcopenia (N = 29)

Sarcopenia (N = 31)

 

n (%)

n (%)

p-value

AE grade ≥ 3 during induction chemotherapy

  

0.78

 No

22 (52.4%)

8 (44.4%)

 

 Yes

20 (47.6%)

10 (55.6%)

 

AE grade ≥ 3 during RC(I)T

  

0.041

 No

20 (47.6%)

3 (16.7%)

 

 Yes

22 (52.4%)

15 (83.3%)

 

Overall surgical complications

  

0.16

 No

24 (57.1%)

6 (33.3%)

 

 Yes

18 (42.9%)

12 (66.7%)

 

Hospitalization during neoadjuvant therapy

  

1

 No

5 (11.9%)

2 (11.1%)

 

 Yes

37 (88.1%)

16 (88.9%)

 

Duration of postoperative hospitalization

Median (range)

18.5 (10.0, 144.0)

20.5 (10.0, 49.0)

0.43

  1. AE Adverse event, RC(I)T Radiochemo (immune) therapy